Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Blinatumomab vs Chemotherapy Among Children With Relapsed Acute Lymphoblastic Leukemia—Reply

Blinatumomab vs Chemotherapy Among Children With Relapsed Acute Lymphoblastic Leukemia—Reply Letters While a cost-effectiveness analysis was beyond the scope balanced between the 2 groups before blinatumomab therapy of our study, the mean total hospital charge was $90 732.59 and whether the percentage of regulatory T cells could pre- for patients treated with ventral fusion and $123 184.43 for dor- dict event-free survival. sal fusion. The total hospital charge for laminoplasty was lower at $59 702.83. Our previously published pilot study had similar Motoharu Shibusawa, MD findings. Amorecomprehensivecost-effectivenessanalysisthat Keisuke Kidoguchi, MD includes outpatient health resource utilization is forthcoming. Tetsuya Tanimoto, MD In our recent trial, we randomized 163 of 458 screened pa- Author Affiliations: Department of Hematology, Shinmatsudo Central General tients, focusing on patients with cervical myelopathy for whom Hospital, Chiba, Japan (Shibusawa); Saga Central Hospital, Saga, Japan clinical equipoise existed regarding treatment with ventral vs (Kidoguchi); Navitas Clinic Kawasaki, Kanagawa, Japan (Tanimoto). dorsal surgery. We agree with Dr Shao and colleagues that the Corresponding Author: Motoharu Shibusawa, MD, Department of results of our trial would not apply to patients who have a clear Hematology, Shinmatsudo Central General Hospital, 1-380 Shinmatsudo, Matsudo-shi, Chiba-ken, 270-0034 Japan (m_sibusawa@hotmail.com). indication for 1 of these surgical procedures over the other. We also agree that http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Blinatumomab vs Chemotherapy Among Children With Relapsed Acute Lymphoblastic Leukemia—Reply

JAMA , Volume 326 (4) – Jul 27, 2021

Loading next page...
 
/lp/american-medical-association/blinatumomab-vs-chemotherapy-among-children-with-relapsed-acute-uzuV6DBMZQ
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2021.8154
Publisher site
See Article on Publisher Site

Abstract

Letters While a cost-effectiveness analysis was beyond the scope balanced between the 2 groups before blinatumomab therapy of our study, the mean total hospital charge was $90 732.59 and whether the percentage of regulatory T cells could pre- for patients treated with ventral fusion and $123 184.43 for dor- dict event-free survival. sal fusion. The total hospital charge for laminoplasty was lower at $59 702.83. Our previously published pilot study had similar Motoharu Shibusawa, MD findings. Amorecomprehensivecost-effectivenessanalysisthat Keisuke Kidoguchi, MD includes outpatient health resource utilization is forthcoming. Tetsuya Tanimoto, MD In our recent trial, we randomized 163 of 458 screened pa- Author Affiliations: Department of Hematology, Shinmatsudo Central General tients, focusing on patients with cervical myelopathy for whom Hospital, Chiba, Japan (Shibusawa); Saga Central Hospital, Saga, Japan clinical equipoise existed regarding treatment with ventral vs (Kidoguchi); Navitas Clinic Kawasaki, Kanagawa, Japan (Tanimoto). dorsal surgery. We agree with Dr Shao and colleagues that the Corresponding Author: Motoharu Shibusawa, MD, Department of results of our trial would not apply to patients who have a clear Hematology, Shinmatsudo Central General Hospital, 1-380 Shinmatsudo, Matsudo-shi, Chiba-ken, 270-0034 Japan (m_sibusawa@hotmail.com). indication for 1 of these surgical procedures over the other. We also agree that

Journal

JAMAAmerican Medical Association

Published: Jul 27, 2021

References